Kenneth Rappaport, DO
Nephrology · Palm Beach Gardens, FLNPI 1447210372
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $649 and has fallen 95.0% since, to $32 in 2025.
Across 107 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$276
- Pfizer$224
- Amarin Pharma, Inc.$198
- Novo Nordisk$197
- Amgen$153
- Bayer$150
- plus $805 from 19 others
What the payments were for
- Food & beverage$1,97999%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 16 | $276 |
| Pfizer | 11 | $224 |
| Amarin Pharma, Inc. | 11 | $198 |
| Novo Nordisk | 11 | $197 |
| Amgen | 9 | $153 |
| Bayer | 7 | $150 |
| Exact Sciences | 6 | $128 |
| GSK | 7 | $121 |
| Otsuka America Pharmaceutical, Inc. | 5 | $106 |
| AbbVie | 3 | $56 |
| Kowa Pharmaceuticals America, Inc. | 3 | $51 |
| AstraZeneca | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Vifor Pharma, Inc. | 2 | $36 |
| Merck | 2 | $31 |
| Boehringer Ingelheim | 1 | $28 |
| Akebia Therapeutics Inc | 1 | $25 |
| Abbott | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Linus Health, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,003 in reported general payments places this provider in the 55th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 22 | $21,998 |
| EliquisApixaban | 19 | $17,315 |
| JardianceEmpagliflozin | 14 | $16,739 |
| ProsolParenteral Amino Acid 20% No.1 | 42 | $6,432 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,508 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $4,967 |
| Rosuvastatin Calcium | 91 | $1,155 |
| Losartan Potassium | 104 | $1,042 |
| Atorvastatin Calcium | 69 | $844 |
| Levothyroxine Sodium | 68 | $829 |
| Temazepam | 13 | $729 |
| Ezetimibe | 22 | $595 |
| Nifedipine ErNifedipine | 14 | $525 |
| Solifenacin Succinate | 13 | $510 |
| Metoprolol Succinate | 24 | $460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $197 | $21,99822 claims |
| PfizerEliquis | $224 | $17,31519 claims |
| Boehringer IngelheimJardiance | $28 | $16,73914 claims |
| GSKAnoro Ellipta | $121 | $5,50811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 756 nephrology providers in Florida.
Other nephrology in Palm Beach Gardens
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.